Oncology Intelligence
Advancing Precision Medicine from Biomarker to Companion Diagnostics
Imagene AI Announces Collaboration with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology
Oncology Intelligence
Advancing Precision Medicine from Biomarker to Companion Diagnostics
Imagene AI Announces Collaboration with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology
Our Oncology Intelligence Engine continuously learns from imaging, molecular, and clinical data through proprietary foundation models, large language models, and biology-tuned analysis engines. It empowers biopharma & clinical teams with advanced capabilities for biomarker discovery, patient stratification, response prediction, and companion diagnostic development. From molecular profiling to AI-powered image analysis, our pathology assays translate biological insights into patient-selection and diagnostic strategies.
A transformative SaaS platform delivering advanced capabilities for biomarker discovery, indication expansion, and patient identification across multiple therapeutic areas.
At its core, is our proprietary Cross-Modality Intelligence Engine, that uncovers insights across histopathology, gene expression, mutational profiles, and clinical records to advance biomarker discovery, improve patient identification and stratification, and optimize trial design, even from small clinical cohorts.
“Tempus is committed to broadly offering AI-enabled diagnostics in an effort to improve patient outcomes. This collaboration with Imagene strengthens our diagnostic offerings and allows us to provide clinicians more actionable data that may lead to additional testing.”
Chris Scotto DiVettaSenior Vice President of AI Products at Tempus 
“CanvOI transforms our approach to healthcare and disease understanding. By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition.”
Dr. David AgusFounding Director and Co-CEO, Ellison Medical Institute
“Oncologists already use clinical features like race and smoking status to manage decision-making when treatment delays pending molecular results are likely to be appropriate. I would definitely use a science-forward, reliable, and ultra-rapid AI test to enhance this process in supporting an informed clinical decision.”
Dr. Ross CamidgeProfessor of Medicine, Director of Thoracic Oncology, University of Colorado
"Imagene's AI-based biomarker detection shows great promise for significantly reducing the waiting time for patients to begin targeted therapies. This kind of technology can lead to better
and earlier cancer care for patients no matter where they live.”
Dr. David R. BraxtonChief of Molecular Pathology Services at Hoag
“Unfortunately, we are so used to waiting a long time for molecular cancer testing while patients deteriorate, that such a breakthrough technology, enabling treatment initiation within a day is exceptional. This is a real revolution; this technology is the future for oncology.”
Professor Ido WolfDirector of Oncology, Sourasky Medical Center
“Saving lives is technology's single most important use. We are proud that Oracle’s highly performant and secure cloud infrastructure will help Imagene improve access to care, drive informed decisions, lower costs, and ultimately save lives.”
Safra CatzCEO, Oracle
"Cancer continues to have a devastating impact on individuals and families, but with advancements in cloud and AI we have an opportunity to help change this narrative. We are proud to be working with companies like Imagene AI to support breakthroughs in oncology that can help improve outcomes for those afflicted with this disease."
Seema VermaEVP & GM, Oracle Health and Life Sciences
"The ability to use Imagene's AI technology under research is a game-changer. It allowed us to bypass the usual lengthy waiting period associated with comprehensive genomic profiling. This technology is revolutionizing the way we diagnose patients, with the potential to improve outcomes and save lives."
Professor Dov HershkovitzHead of Pathology, Sourasky Medical Center
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Professor Iris BarshackHead of the Pathology Institute, Sheba Medical Center
“CanvOI transforms our approach to healthcare and disease understanding. By providing access to comprehensive oncology intelligence in the cloud, it enables researchers to develop answers quicker and more efficiently. This technology marks a new era of cancer research that pushes us closer to a future where cancer is a manageable condition.”
Dr. David AgusFounding Director and Co-CEO, Ellison Medical Institute
“Tempus is committed to broadly offering AI-enabled diagnostics in an effort to improve patient outcomes. This collaboration with Imagene strengthens our diagnostic offerings and allows us to provide clinicians more actionable data that may lead to additional testing.”
Chris Scotto DiVettaSenior Vice President of AI Products at Tempus
“Saving lives is technology's single most important use. We are proud that Oracle’s highly performant and secure cloud infrastructure will help Imagene improve access to care, drive informed decisions, lower costs, and ultimately save lives.”
Safra CatzCEO, Oracle
"Imagene's AI-based biomarker detection shows great promise for significantly reducing the waiting time for patients to begin targeted therapies. This kind of technology can lead to better
and earlier cancer care for patients no matter where they live.”
Dr. David R. BraxtonChief of Molecular Pathology Services at Hoag
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Seema VermaEVP & GM, Oracle Health and Life Sciences
“Oncologists already use clinical features like race and smoking status to manage decision-making when treatment delays pending molecular results are likely to be appropriate. I would definitely use a science-forward, reliable, and ultra-rapid AI test to enhance this process in supporting an informed clinical decision.”
Dr. Ross CamidgeProfessor of Medicine, Director of Thoracic Oncology, University of Colorado
“Unfortunately, we are so used to waiting a long time for molecular cancer testing while patients deteriorate, that such a breakthrough technology, enabling treatment initiation within a day is exceptional. This is a real revolution; this technology is the future for oncology.”
Professor Ido WolfDirector of Oncology, Sourasky Medical Center
"The ability to use Imagene's AI technology under research is a game-changer. It allowed us to bypass the usual lengthy waiting period associated with comprehensive genomic profiling. This technology is revolutionizing the way we diagnose patients, with the potential to improve outcomes and save lives."
Professor Dov HershkovitzHead of Pathology, Sourasky Medical Center
“We have reached another significant milestone in digital pathology with this ability to detect biomarkers by AI. The use of deep learning algorithms is changing the world of diagnosis, and in certain cases can drastically shorten the cost and time to treatment. I am excited to hear about the growing number of patients who were able to receive rapid diagnoses and treatment.”
Professor Iris BarshackHead of the Pathology Institute, Sheba Medical Center
Our Medical Advisory Board
World-Leading Experts at the Forefront of Healthcare & Precision Oncology
Founding CEO Ellison Medical Institute
David Agus, MD. 
Princess Margaret Cancer Centre, University of Toronto
Natasha Leighl, MD. 
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD., PhD. 
University of Colorado Cancer Center, Aurora, Colorado
Ross Camidge, MD., PhD. 
Dept. of Clinical Oncology
Chinese University, Hong Kong
Tony Mok, MD. 
Anatomical, molecular, genomic, digital and translational pathologist
Paul Waring, MD., PhD. 
David Agus, MD.
Founding CEO
Ellison Medical Institute
Natasha Leighl, MD.
Princess Margaret Cancer Centre, University of Toronto
Christian Rolfo, MD., PhD.
The Ohio State University Comprehensive Cancer Center
Ross Camidge, MD., PhD. University of Colorado Cancer Center, Aurora, Colorado
Tony Mok, MD.
Dept. of Clinical Oncology
Chinese University, Hong Kong
Paul Waring, MD., PhD.
Translational Pathologist